Nuclear receptor coactivator 2 (NCoA-2) is a transcriptional coactivator protein encoded by the NCOA2 gene in humans. It acts by interacting with ligand-activated nuclear hormone receptors—including steroid, thyroid, retinoid, and vitamin D receptors—and facilitating transcriptional activation. This protein contains several nuclear receptor interaction domains and intrinsic histone acetyltransferase activity, enabling it to remodel chromatin structure to promote gene transcription. NCoA-2 is essential in regulating genes involved in energy balance, metabolism, and the circadian clock, as well as mediating hormone receptor signaling transduction. It is also a partner in pathological gene fusions associated with certain cancers, underscoring its relevance as a biomarker and potential drug target in oncology and metabolic research.
Other names
NCoA-2SRC-2 (steroid receptor coactivator-2)GRIP1 (glucocorticoid receptor-interacting protein 1)TIF2 (transcriptional intermediary factor 2)hTIF2BHLHE75Class E basic helix-loop-helix protein 75Transcriptional intermediary factor 2
02
Mechanism of action
Modulation of hormonal receptor signaling through coactivation; Enhancement of transcriptional activity of nuclear receptors after ligand binding; Indirect chromatin modification and transcription initiation via recruitment to promoter regions.
03
Biological functions
Regulation of gene transcription (by RNA polymerase II)Coactivation of nuclear receptors (including steroid, thyroid, retinoid, and vitamin D receptors)Chromatin remodeling (histone acetyltransferase activity)Energy balance regulation (white and brown adipose tissue)Glucose metabolism regulationCircadian clock regulationResponse to hormones (e.g., glucocorticoids, progesterone)
04
Disease associations
Cancer (particularly as NCOA2 gene fusions are implicated in various cancers, including leukemia and sarcomas; overexpression has roles in tumor growth and progression)Metabolic disorders (due to roles in glucose metabolism and adipose regulation)Other (potential implication in hormone-related diseases and endocrine disorders)
05
Safety considerations
Targeting coactivators such as NCoA-2 risks broad, pleiotropic effects on hormone signaling and gene transcription, resulting in potential metabolic, developmental, or oncologic side effects if not highly specific.Gene alterations may contribute to oncogenesis if not carefully regulated.
06
Interacting drugs
No FDA-approved small-molecule drugs are known to target Nuclear receptor coactivator 2 directly as of 2025. It is mainly a coregulator rather than a traditional receptor, enzyme, or ion channel drug target.
07
Biomarkers
NCOA2 gene rearrangements/fusions serve as biomarkers in specific cancers such as mesenchymal chondrosarcoma and some leukemias; overexpression may be a marker in certain solid tumors, but routine clinical use is limited.
Beyond the preview
Go deeper on Nuclear receptor coactivator 2 (NCoA-2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear receptor coactivator 2 (NCoA-2).